Evidence map›Paper›PMID 32118712›Full record

Observational studyMedicine2020

Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis.

Sangdeok Shin, Sang Hoon Lee, Minjong Lee, Ji Hyun Kim, Wongu Lee, Hyun Woo Lee, Min Soo Park, Seungwoo Park, Tae Suk Kim, Dae Hee Choi

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 6 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 6 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Chemoprevention of hepatocellular carcinoma.Hepatology communications · 2025
    Review
  8. Current and emerging strategies for the prevention of hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sangdeok ShinDepartment of Internal Medicine, Kangwon National University School of Medicine, Chuncheon.
Sang Hoon LeeDepartment of Internal Medicine, Kangwon National University School of Medicine, Chuncheon.
Minjong LeeDepartment of Internal Medicine, Kangwon National University School of Medicine, Chuncheon.
Ji Hyun KimDepartment of Internal Medicine, Kangwon National University School of Medicine, Chuncheon.
Wongu LeeDepartment of Internal Medicine, Kangwon National University School of Medicine, Chuncheon.
Hyun Woo LeeDepartment of Internal Medicine, Kangwon National University School of Medicine, Chuncheon.
Min Soo ParkDepartment of Internal Medicine, Kangwon National University School of Medicine, Chuncheon.
Seungwoo ParkDepartment of Internal Medicine, Kangwon National University School of Medicine, Chuncheon.
Tae Suk KimDepartment of Internal Medicine, Kangwon National University School of Medicine, Chuncheon.
Dae Hee ChoiDepartment of Internal Medicine, Kangwon National University School of Medicine, Chuncheon.
Kangwon National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aspirin therapy has shown protective effects against hepatocellular carcinoma (HCC) in preclinical studies. However, it is unclear whether aspirin therapy lowers the risk of HCC in patients with alcoholic cirrhosis.A retrospective analysis of data from 949 consecutive patients with alcoholic cirrhosis who abstained from alcoholic drinking was performed. The primary and secondary outcomes were development of HCC and gastrointestinal bleeding events, respectively. Risk was compared between patients with aspirin treatment and patients who were not treated (non-aspirin group) using a time-varying Cox proportional hazards model for total population and propensity score-matching analysis.The aspirin group included 224 patients and the non-aspirin group had 725 patients. During the study period of median duration of 3.1 years, 133 patients (13.6%) developed HCC. In time-varying Cox proportional analyses, the aspirin group showed a significantly lower risk of HCC (adjusted hazard ratio [aHR]: 0.13; 95% confidence interval [CI]: 0.08-0.21; P < .001). In propensity score-matched pairs, aspirin therapy significantly reduced the risk of HCC (aHR: 0.14; 95% CI: 0.09-0.22; P < .001). In bleeding risk, treatment with aspirin alone was not significantly associated with a higher bleeding risk (aHR: 0.81; 95% CI: 0.45-1.44; P = .46).Aspirin therapy was associated with the lower risk of HCC in patients with alcoholic cirrhosis.

Indexed as

AgedAspirinCarcinoma, HepatocellularFemaleHumansIncidenceLiver Cirrhosis, AlcoholicLiver NeoplasmsMaleMiddle AgedPlatelet Aggregation InhibitorsRepublic of KoreaRetrospective StudiesAspirinPlatelet Aggregation Inhibitors

Identifiers

PMID32118712
PMCPMC7478404
OpenAlexW3009744363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.